Bupropion does produce weight loss, though the amount is modest compared to newer obesity medications. Across pooled clinical trials, bupropion alone leads to roughly 3 to 4 kilograms of weight loss beyond what placebo achieves, and the FDA-approved combination of bupropion with naltrexone (sold as Contrave) roughly doubles that effect. Whether that counts as “actually working” depends on your expectations and your starting point, and the story gets more interesting when you look at who benefits most and why.
How Much Weight Bupropion Alone Takes Off
When researchers pool the results of randomized controlled trials testing bupropion by itself against a placebo, the average additional weight loss comes to about 3.7 kilograms, with a reduction in waist circumference of about 3 centimeters.1PubMed Central. The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials That is roughly 8 pounds on a scale. For someone who weighs 220 pounds, losing 8 more pounds than they would have lost without the drug amounts to a few percent of their body weight. It is real, it is statistically consistent across studies, and for some people it makes a meaningful difference in how clothes fit or how blood sugar behaves. But it is not the kind of dramatic change that newer injectable medications can produce.
Bupropion was never designed as a weight-loss drug. It was developed as an antidepressant and later approved for smoking cessation, and the weight loss was initially noticed as a side effect. That origin story matters because it helps explain why bupropion’s weight effects are moderate: the drug was optimized to treat depression, not obesity. The doses used in weight-management studies are the same as those prescribed for mood, typically 300 to 450 milligrams per day of the sustained-release formulation.
What Happens When You Add Naltrexone
The combination of naltrexone and bupropion is the version that has formal FDA approval for chronic weight management. Naltrexone is an opioid receptor blocker originally used for alcohol and opioid dependence, and when paired with bupropion it amplifies the weight-loss effect beyond what either drug achieves alone.2PubMed. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity The two drugs act on overlapping but distinct brain circuits involved in appetite and reward, which is why the combination outperforms either component.
In the largest randomized trial of the combination, participants taking the higher-dose version lost an average of about 6% of their body weight over 56 weeks, compared with roughly 1.3% for placebo. Nearly half of those on the active drug lost at least 5% of their starting weight, versus about 16% on placebo.3The Lancet. Effect of combination therapy of naltrexone plus bupropion on body weight in overweight and obese adults (COR-I): a randomised, placebo-controlled trial When four large phase 3 trials are pooled together, the placebo-subtracted weight loss averages about 4.7% of body weight after one year, and the proportion of people who hit that clinically meaningful 5% threshold ranges from about 26% to 33% more than placebo.4Obesity Facts. Naltrexone/Bupropion: An Investigational Combination for Weight Loss and Maintenance
To put those numbers in context: a 5% loss of body weight in someone who weighs 250 pounds is about 12.5 pounds. That may not sound like a lot, but research consistently shows that losing even 5% of body weight improves blood pressure, blood sugar control, and cholesterol profiles. The combination also appears to help people keep the weight off. In a trial of people who had already lost weight through an intensive lifestyle program, those who then took naltrexone-bupropion were more likely to maintain their losses over six months than those on placebo.5PubMed Central. Effect of Naltrexone HCl and Bupropion HCl (Contrave) Extended-Release Tablet (NB-ER) for Weight Maintenance in Adult Patients After a 6-Month Intensive Behaviour Modification Program Combined With Meal Replacements
How It Changes the Way Your Brain Responds to Food
Bupropion blocks the reuptake of dopamine and norepinephrine, which increases the availability of those chemical messengers in parts of the brain that regulate energy, motivation, and reward. In the hypothalamus, this shift promotes the release of appetite-suppressing signals. In the brain’s reward circuits, it changes how strongly you respond to food cues. The naltrexone component layers on by blocking opioid receptors, which removes a feedback loop that would otherwise dampen bupropion’s appetite-suppressing effects.6PubMed Central. Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy
Brain-imaging studies have shown what this looks like in practice. When people taking the naltrexone-bupropion combination were shown pictures of food, activity in the hypothalamus (the brain’s hunger thermostat) went down, while activity in regions responsible for self-control and internal awareness went up.7International Journal of Obesity. Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues Separately, the combination appeared to alter connectivity in the brain’s reward pathways in ways that reduce the craving response to food cues.8PubMed Central. Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity In simpler terms, the drug doesn’t just make you less hungry. It makes you less drawn to food when you see it or smell it, which for many people is a bigger driver of overeating than physical hunger.
This craving-reduction mechanism is part of what makes bupropion-based treatment different from simple appetite suppressants. Food cravings driven by reward-seeking rather than genuine hunger are a major reason people struggle with weight management, and addressing them pharmacologically is one of the goals of modern obesity treatment.9PubMed Central. Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings
The Antidepressant That Doesn’t Cause Weight Gain
If you are taking bupropion for depression or anxiety and wondering about its weight effects, here is the standout finding: bupropion is the only commonly prescribed antidepressant that is consistently linked to weight loss or weight neutrality rather than weight gain.10PubMed Central. Impact of Antidepressants on Weight Gain: Underlying Mechanisms and Mitigation Strategies Most other classes, including SSRIs, tricyclics, and mirtazapine, tend to cause weight gain over months to years of use.
A large observational study that compared weight changes across antidepressant prescriptions found that over six months, people on bupropion gained slightly less weight than those on sertraline (by about a fifth of a kilogram on average) and were about 15% less likely to gain 5% or more of their body weight. Meanwhile, drugs like escitalopram, paroxetine, and duloxetine were associated with 10% to 15% higher risk of that kind of weight gain.11PubMed Central. Medication-Induced Weight Change Across Common Antidepressant Treatments: A Target Trial Emulation Study A separate meta-analysis of bupropion’s antidepressant effectiveness found that beyond being effective for depression, it carries low rates of sexual dysfunction and is more likely to cause weight loss than weight gain, which makes it a particularly useful choice for people concerned about those side effects.12PubMed Central. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant
This is genuinely unusual. If you need an antidepressant and also want to lose weight or at least not gain any, bupropion is essentially the only standard option that works in your favor on both fronts. Many clinicians factor this in when choosing an antidepressant for patients who are already overweight or who have gained weight on a previous medication.
Binge Eating Disorder Is a Different Story
Given that bupropion reduces food cravings and reward-driven eating, you might expect it to help with binge eating disorder. The evidence here is surprisingly disappointing. A randomized trial of bupropion alone in overweight women with binge eating disorder found that the drug did not improve binge eating episodes, food cravings, or related eating disorder features compared to placebo.13PubMed Central. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial
The naltrexone-bupropion combination performs better, but the picture is mixed. One trial found that the combination did not reduce binge eating compared to placebo, though it did produce meaningful weight loss in those same patients.14PubMed Central. Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial A separate study tested the combination alongside behavioral weight loss therapy and found that naltrexone-bupropion did improve binge eating remission rates beyond placebo (about 31% remission versus about 18% for placebo), and the strongest results came when the medication was paired with behavioral therapy, where remission hit about 57%.15PubMed Central. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
The takeaway is that if binge eating is your primary concern, bupropion on its own is not the answer. The combination with naltrexone may help, especially alongside structured behavioral support, but the evidence is inconsistent enough that it would not be a first-line choice for binge eating disorder specifically. You may lose weight on it, but your binge episodes may or may not change.
Quitting Smoking Without Gaining Weight
Bupropion has a second FDA-approved use as a smoking cessation aid (sold under the brand name Zyban), and one of its practical benefits in that context is blunting the weight gain that commonly follows quitting. People who quit smoking typically gain weight, partly because nicotine suppresses appetite and partly because food starts tasting better once the tongue’s taste receptors recover. Early trials suggested bupropion might limit this weight rebound, and later data confirmed it: one study found that people taking bupropion after quitting gained about 3.8 kilograms at one year, compared with 5.6 kilograms for those on placebo, a difference that persisted at two years.16PubMed. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial
That said, the effect is not dramatic enough to prevent all post-cessation weight gain. In a trial focused specifically on weight-concerned women smokers, those taking bupropion still gained about 5 kilograms over three months of abstinence, similar to the other study arms.17PubMed Central. Bupropion and Cognitive Behavioral Therapy for Weight-Concerned Women Smokers The benefit appears to be a reduction in post-quit weight gain rather than outright prevention of it. Reviews of the smoking cessation literature describe a modest effect on reducing post-cessation weight gain during the treatment phase, though how long that advantage lasts without continued medication use remains uncertain.18Mayo Clinic Proceedings. Bupropion Sustained Release for Treatment of Tobacco Dependence If you are quitting smoking and concerned about gaining weight, bupropion offers a genuine two-for-one benefit, but plan on some weight gain anyway.
Blood Pressure and Heart Rate Considerations
One concern with bupropion and the naltrexone-bupropion combination is the effect on cardiovascular markers. Bupropion can modestly raise blood pressure and heart rate in some people, and when you combine it with naltrexone those effects do not disappear. A large cardiovascular outcomes trial of naltrexone-bupropion in overweight and obese people with cardiovascular risk factors found small average increases: blood pressure went up by less than half a millimeter of mercury and heart rate increased by less than one beat per minute compared to placebo after 16 weeks.19JAMA. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial
Those average numbers sound reassuring, and for most people they probably are. But averages can hide individual variation. Some people experience more noticeable blood pressure increases, which is why prescribing guidelines typically recommend monitoring blood pressure during the first few months of treatment. The cardiovascular outcomes trial itself was terminated early due to the premature release of interim data, so it did not fully answer whether the combination affects rates of heart attacks or strokes in the long term. The available data suggest no alarming signal, but the evidence base is not as complete as clinicians would like.
This matters most if you already have high blood pressure or other cardiovascular risk factors. The weight loss from the medication may improve your metabolic profile in ways that benefit heart health, and trials have noted improvements in cardiometabolic markers alongside the weight loss.20PubMed. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes But the trade-off between weight-related metabolic improvements and a small blood pressure bump is something to discuss with your doctor, especially if your blood pressure is already borderline.
Why Some People Respond More Than Others
If you have taken bupropion and noticed no appetite change at all, your liver enzymes might be part of the explanation. Bupropion is metabolized primarily by an enzyme called CYP2B6, and genetic variants of this enzyme are common. People carrying certain gene variants (known as CYP2B6*6 and *18) produce about a third less of one of bupropion’s active metabolites, hydroxybupropion, which is thought to contribute substantially to the drug’s effects.21PubMed Central. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state Genotype and sex together accounted for about half of the variation in hydroxybupropion levels in one study. So two people taking the same dose could have meaningfully different drug exposures, which likely affects both the weight-loss response and the side effect profile.
Beyond genetics, other factors influence how much weight you lose on bupropion. People whose overeating is driven more by reward-seeking and cravings than by genuine hunger are the most likely to benefit, given the drug’s mechanism. People who are also depressed may see a synergistic effect where improved mood makes it easier to exercise and make dietary changes. And as with any weight-loss approach, the baseline matters: someone with 100 pounds to lose will not get there on bupropion alone, while someone trying to shed 15 to 20 pounds might find the boost meaningful.
Adolescents and Younger Adults
Bupropion has been used in adolescents aged 12 to 17 for depression, and weight loss has been noted as a side effect in those patients. However, there are important safety caveats. Like some other antidepressants, bupropion carries a black-box warning about the risk of increased suicidal thoughts in children, adolescents, and young adults with psychiatric disorders. The naltrexone-bupropion combination (Contrave) is not approved for anyone under 18, and as of now there are no pediatric studies investigating its effects on childhood or adolescent obesity.22PubMed Central. Medications for the treatment of obesity in adolescents Bupropion monotherapy is also not FDA-approved for the treatment of depression or any other condition in youth. If a pediatrician prescribes it off-label and weight loss occurs as a side effect, that is a different situation from intentionally using the drug for weight management in a young person.
Seizure Risk and Who Should Avoid It
Bupropion lowers the seizure threshold, and this is the most significant safety concern unique to the drug. The risk is dose-dependent, meaning it climbs as the dose increases, which is why there is a ceiling on the recommended daily amount. People with a history of seizures, eating disorders involving purging (which can cause electrolyte imbalances that further lower the seizure threshold), or heavy alcohol use are generally advised not to take bupropion. The sustained-release and extended-release formulations were developed in part to reduce seizure risk compared to the original immediate-release version, which had a notably higher seizure rate at higher doses.
The eating disorder connection is worth flagging specifically. If someone has bulimia or anorexia with purging behaviors, bupropion is typically contraindicated because of the compounded seizure risk. This creates a somewhat awkward clinical gap: a drug that helps with weight management and food cravings cannot be safely given to some of the people who struggle most with disordered eating. For people with binge eating disorder who do not purge, the seizure risk is the same as in the general population, but the clinical benefit for binge eating itself is limited, as discussed earlier.
How Bupropion Stacks Up in the Current Landscape
The honest framing is that bupropion-based weight loss is modest by current standards. The GLP-1 receptor agonists (semaglutide and tirzepatide) can produce weight loss of 15% or more of body weight, which dwarfs the roughly 4 to 5% placebo-subtracted loss from naltrexone-bupropion. But those drugs are expensive, often require injections, have their own side effect profiles including significant gastrointestinal symptoms, and are not always covered by insurance. Naltrexone-bupropion is an oral medication, which some people prefer, and generic bupropion is inexpensive when used off-label on its own.
The role bupropion tends to fill in practice is more targeted than “make me lose a lot of weight.” It works best for people who need an antidepressant anyway and want to avoid weight gain, people who are quitting smoking and want to limit post-cessation pounds, people whose overeating is driven by cravings and reward-seeking rather than hormonal hunger, and people who want a modest boost alongside diet and exercise changes but do not qualify for or want injectable medications. Expecting it to compete head-to-head with the newest obesity drugs sets it up to disappoint. Recognizing what it actually does well, and for whom, makes the picture considerably more useful.